Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy

Expert Review of Clinical Immunology

Volumn 7, Issue 1, 2011, Pages 21-27

  Senna, Gian Enrico ^a   Calderon, Moises ^b   Milani, Massimo ^c  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c Medical Department   (Italy)

Author keywords

grass pollen allergy; immunotherapy; rhinoconjunctivitis; sublingual immunotherapy; tablet

Indexed keywords

ALLERGEN; ALUTARD; ALUTARD SQ; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; GRASS POLLEN VACCINE; IMMUNOGLOBULIN G4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OLANZAPINE; PLACEBO; SELEGILINE; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ALLERGY IMMUNOTHERAPY TABLET; ARTICLE; ASTHMA; CONJUNCTIVITIS; COUGHING; CROSS REACTION; DISEASE CONTROL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EAR PRURITUS; FATIGUE; GRASS POLLEN; HAY FEVER; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; LYOPHILISATE; MOUTH EDEMA; MOUTH PARESTHESIA; MOUTH PRURITUS; MULTICENTER STUDY (TOPIC); NOSE CONGESTION; OCULAR PRURITUS; PATIENT COMPLIANCE; PEDIATRICS; PERENNIAL RHINITIS; PHARMACODYNAMICS; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHLEUM PRATENSE; POLLEN ALLERGY; PRURITUS; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHINITIS; RHINOCONJUNCTIVITIS; RHINORRHEA; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SNEEZING; SORE THROAT; SYMPTOM; TABLET FORMULATION; THROAT IRRITATION; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, SUBLINGUAL; ADULT; CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; PLANT EXTRACTS; POACEAE; POLLEN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, SEASONAL; TABLETS; TREATMENT OUTCOME;

EID: 78650533160     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.89     Document Type: Article

References (44)

1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur. Respir. J. 24, 758-764 (2004).
2. Dahl R, Andersen P, Chivato T, Valovirta E, de Monchy J. National prevalence of respiratory allergic disorders. Respir. Med. 98, 398-403 (2004).
3. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J. Allergy Clin. Immunol. 120, 381-387 (2007).
4. Passalacqua G, Ciprandi G, Canonica GW. The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Curr. Opin. Allergy Clin. Immunol. 1, 7-13 (2001).
5. White P, Smith H, Baker N et al. Symptom control in patients with hayfever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clin. Exp. Allergy 28, 266-270 (1998).
6. Sundberg R, Toren K, Hoglund D, Aberg N, Brisman J. Nasal symptoms are associated with school performance in adolescents. J. Adolesc. Health 40, 581-583 (2007).
7. Bruce M. Allergic rhinitis: treatment based on patient profiles. Am. J. Med. 119, 230-237 (2006).
8. Plaut M, Valentine MD. Clinical practice. Allergic rhinitis. N. Engl. J. Med. 353, 1934-1944 (2005).
9. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 63(Suppl. 86), 8-160 (2008). (Pubitemid 351357811)
10. Canonica GW. A survey of the burden of allergic rhinitis in Europe. Allergy 62(Suppl. 85), 17-25 (2007).
11. Linneberg A. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy 57, 1048-1052 (2002).
12. Wilson AM, O Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am. J. Med. 116, 338-344 (2004).
13. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 119, 780-789 (2007).
14. Passalacqua G, Guerra L, Pasquali M, Canonica GW. Efficacy and safety of sublingual immunotherapy. Ann. Allergy Asthma Immunol. 93, 3-12 (2004).
15. Wilson DR, Torres L, Durham SR. Sublingual immunotherapy for allergic rhinitis. Allergy 60, 3-8 (2005).
16. Bousquet J, Lockey RF, Malling HJ. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53, 1-42 (1998). (Pubitemid 28346358)
17. Wilson DR, Torres LM, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60, 4-12 (2005).
18. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117, 802-809 (2006).
19. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J. Pharm. Pharmacol. 50(4), 375-382 (1998).
20. Poston KL, Waters C. Zydis selegiline in the management of Parkinsons disease. Expert Opin. Pharmacother. 8(15), 2615-2624 (2007).
21. Malling H-J, Lund L, Ipsen H, Poulsen LK. Safety and immunological changes during specific sublingual immunotherapy with SQ standardized grass allergen tablets. J. Investig. Allergol. Clin. Immunol. 16, 162-168 (2006).
22. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual once-daily grass-pollen immunotherapy: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117, 802-809 (2006).
23. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 62, 958-961 (2007).
24. Weber RW. Cross-reactivity of pollen allergens: recommendations for immunotherapy vaccines. Curr. Opin. Allergy Clin. Immunol. 5, 563-569 (2005).
25. EMEA Guidelines. Committee for medicinal products for human use. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/ EWP/18504/2006 (2007).
26. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 118, 434-440 (2006).
27. Dahl R, Kapp A, Colombo G et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J. Allergy Clin. Immunol. 121, 512-518 (2008).
28. Durham SR, Emminger W, Kapp A et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J. Allergy Clin. Immunol. 125, 131-138 (2010).
29. Malling HJ. Sublingual immunotherapy: efficacy - methodology and outcome of clinical trials. Allergy 61(Suppl. 81), 24-28 (2006).
30. Frew A. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117, 319-325 (2006).
31. Bufe A, Eberle P, Franke-Beckmann E et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J. Allergy Clin. Immunol. 123, 167-173 (2009).
32. Blaiss M, Maloney J, Nolte H, Gawchik S, Skoner D. Efficacy and safety of grass allergy immunotherapy tablet (AIT) in a North American pediatric population. J. Allergy Clin. Immunol. 125(2), (Suppl. 1) AB358 (2010).
33. Canonica GW, Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 62, 317-324 (2007).
34. Andersen JS, Durham S, Emminger W. Increased clinical effect of the ALK grass allergen tablet over 3 years of continued treatment. Presented at: XXVII EAACI Congress. Barcelona, Spain, 7-11 June 2008.
35. Haynes RB, Taylor DW, Sackett DL. Compliance in Health Care. Johns Hopkins University Press, MD, USA (1979).
36. Milani M, Pecora S, Alesina R. A randomized, parallel-group, Phase IV, open trial evaluating compliance to the treatment with Grazax allergen immunotherapy tablet in patients with seasonal grass pollen rhinoconjuntivitis. Allergy 65(Suppl. 92), 209-682 (2010).
37. Malling H-J, Lund L, Ipsen H, Poulsen LK. Safety and immunological changes during specific sublingual immunotherapy with SQ standardized grass allergen tablets. J. Investig. Allergol. Clin. Immunol. 16, 162-168 (2006).
38. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 61, 181-184 (2006).
39. Calderon M, Essendrop M. Specific immunotherapy with high dose SQ standardised grass allergen tablets was safe and well tolerated. J. Investig. Allergol. Clin. Immunol. 16, 338-344 (2006).
40. Ibanez MD, Kaiser F, Knecht R et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr. Allergy Immunol. 18, 516-522 (2007).
41. Scadding GK, Richards DH, Price MJ. Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. Clin. Otolaryngol. Allied Sci. 25, 551-557 (2000).
42. Martin JM, Shalaby K. Immunotherapy as a disease modifier. Paediatr. Res. Rev. 7, S106-S107 (2006).
43. Jacobsen L, Niggemann B, Dreborg S et al. (The PAT investigator group). Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62, 943-948 (2007).
44. Di Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin. Exp. Allergy 33, 206-210 (2003).